Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound. Disclaimer

LimitlessLab
Search the library Wishlist Cart, items: 0
CJC-1295 (with DAC)

Growth Hormone & Muscle

CJC-1295 (with DAC)

Also known as DAC:GRF, CJC-1295 DAC, CJC

Limited human evidenceNot approvedWADA prohibited

Price range: €76 through €150

Discussed for: Raise GH and IGF-1 for muscle, fat loss, recovery.

Sequence: not listed. Modified or non-standard residues are left out on purpose.

Effect strengthHow hard it acts on the body7/10
Proof levelHow well that is shown in humans4/10
Risk levelHow much can go wrong6/10

Editorial 1 to 10 estimates from published research, not measured values. How to read these

Save to wishlist
Save to wishlist

01 / Identity

What it is

CJC-1295 (with DAC) is a synthetic GHRH analog (30 aa + DAC). Main reported uses: raise GH and IGF-1 for muscle, fat loss, recovery. Current status: not approved anywhere. FDA flagged it as a compounding safety risk (2023).

Molecule type
Synthetic GHRH analog (30 aa + DAC)
How it is taken
Injection (SC)
Other names
DAC:GRF, CJC-1295 DAC, CJC

Route only. This library does not publish doses or protocols.

02 / Mechanism

How it is thought to work

GHRH analog that makes the pituitary release more GH for days (long half-life)

Mechanisms seen in cells or animals do not always happen the same way in people.

03 / Potential benefits

What people use it for

Raise GH and IGF-1 for muscle, fat loss, recovery

Limited human evidence

Small or low-quality human data. Most of what is claimed comes from animals, cells or anecdotes.

Listed uses are what people use it for, not proven outcomes.

04 / Known risks

Side effects and risks

Water retention, flushing, numb hands, raised blood sugar; one death in a trial participant (cause unclear)

Risk level 6 of 10

Moderate risk score: real side effects are known, and long-term safety is not settled.

Unknown long-term effects count as a risk, not as a clean record.

05 / Regulatory

Regulatory status

Status
Not approved
Details
Not approved anywhere. FDA flagged it as a compounding safety risk (2023)
Sport (WADA)
Yes: S2 (peptide hormones / GH factors)

Status reflects information up to mid-2026 and changes over time. Check current sources.

06 / Evidence quality

How good is the evidence?

Limited: small human trials

How we grade evidence

07 / Notes and sources

Notes and sources

  • In 2023 the FDA placed it on its list of bulk substances with significant safety concerns for compounding.
  • Growth-factor peptides carry a theoretical risk of feeding existing cancers.
  • Products sold online as research peptides are unregulated. Tests of such products often find wrong amounts, impurities or a different compound.
  • Anyone using compounds like this regularly should have medical supervision and bloodwork (for example IGF-1, glucose and HbA1c, hormones, lipids).
  • Source: Peptide Reference Table, an editorial review of published research up to mid-2026. Scores are 1 to 10 editorial estimates, not measured values. Regulatory and WADA status change over time.

Educational information only. Not medical advice. Talk to a qualified healthcare professional before using any compound.

Related compounds